OmegaGenesis is a biotechnology company based in California and founded in February 2008 with the purpose of creating therapeutic applications based on rare earth nano material discovery. The Company's research is focused on nano-scale materials that promote or inhibit angiogenesis, the growth of new blood vessels.

OmegaGenesis is developing suitable nano-materials to manage human body functions at nano scale (the cell and sub-cell level) accelerating cellular-based biologic therapies where the growth of blood vessels determines the therapeutic outcome. These nano-materials will enable Physicians to treat disease at sub-cellular level in a non-destructive manner instead of treating the disease at the organ or tissue level.

Omega Genesis has licensed technology from Mayo Clinic involving a number of nano-materials made of rare earth elements that promote angiogenesis. OmegaGenesis is translating the fundamental research conducted at Mayo Clinic into the product development process and ultimately medical applications.

The OmegaGenesis nanotechnology platform has broad therapeutic potential for a variety of medical applications. The Company's nanotechnology supplements the natural human angiogenesis process to re-enable processes that are dormant or diminished. OmegaGenesis is the first to use nutrient enhancement through new capillary growth to heal wounds and tissues by activating dormant cells.

Rare earth element nano-materials that promote angiogenesis can potentially be used for wound healing, the treatment of diabetic foot ulcers and thus decreasing the frequency of amputations, hair re-growth, repair of ischemic heart damage and promoting bone formation.

The core technology platform provides for future development in the area of anti-angiogenesis applications. Anti-angiogenic nano materials may effectively treat cancer by depriving the tumor cells of the oxygen and nutrition needed to grow and spread to neighboring tissues. Rare earth nano materials may also have additional applications in medical imaging and diagnostics.

"Every 30 seconds someone loses a leg because of diabetes and a non-healing wound. Most of these occur because of wounds. This technology may have the potential to alter the balance of power between healing and amputation."

David G. Armstrong, DPM, MD, PhD, Professor of Surgery, University of Arizona College of Medicine

"Two of the most common causes of death are heart attacks and strokes. Both of these diseases are increased in patients with diabetes. The technology OmegaGenesis is developing has the potential to enhance diabetic wound healing and may prevent death and disability in these two devastating diseases."

Harold F. Dvorak, MD, Mallinckrodt Distinguished Professor of Pathology Beth Israel Deaconess Medical Center, Boston, MA